Genomics based individualized care for people with neurological conditions.
Mable (Neurolytic Healthcare) has raised $3.2M in total funding. The most recent round was Seed. The last funding was announced in July 2022.
Mable (Neurolytic Healthcare)'s investors include Y Combinator, Creative Destruction Lab, Initialized Capital, Illumina, Arkitekt Ventures.
Mable (Neurolytic Healthcare) is headquartered in Oxford, United Kingdom.
Genomics based individualized care for people with neurological conditions.
Mable (Neurolytic Healthcare) is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Mable (Neurolytic Healthcare) — Funding & Investors." VCBacked, July 27, 2022, https://www.vcbacked.co/company/mable-neurolytic-healthcare. Accessed November 13, 2026.
VCBacked. (2022). Mable (Neurolytic Healthcare) — Funding & Investors. Retrieved November 13, 2026, from https://www.vcbacked.co/company/mable-neurolytic-healthcare
{{cite web |title=Mable (Neurolytic Healthcare) — Funding & Investors |url=https://www.vcbacked.co/company/mable-neurolytic-healthcare |website=VCBacked |access-date=November 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Mable (Neurolytic Healthcare)? Request a listing update